Physician profile
Rachel Mitchell
NPI 1770058372
$2,066.85
in general payments reported to CMS, 2019-2025
15 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $667 · 2022: $575 · 2023: $321 · 2024: $153 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820 · Travel and Lodging: $5.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.55 |
| Travel and Lodging | $5.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $384.87 | 2021-2023 | Farxiga |
| Amgen INC. | $325.05 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $222.66 | 2021-2023 | Xarelto |
| Edwards Lifesciences Corporation | $209.41 | 2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $201.47 | 2022 | |
| Boston Scientific Corporation | $145.91 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $145.62 | 2022-2023 | Eliquis |
| Abbott Laboratories | $129.75 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.16 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $71.02 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.71 | 2022-2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $25.79 | 2021 | |
| Philips North America LLC | $22.75 | 2024 | (5044) Mcot |
| Sanofi-Aventis U.S. LLC | $21.12 | 2021 | |
| Esperion Therapeutics, INC. | $14.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.